OVID

2.2055.77%
JM

Jeremy Max Levin

Executive Chair & CEO

Dr. Jeremy Max Levin, M.D., Ph.D., BA Zoology, DPhil, MB BChir, is Executive Chairman of Ovid Therapeutics Inc. from January 1, 2026 and has been its Chairman since April 2014 and serves as its Director since 2015 and had been its Chief Executive Officer since March 2015 until January 1, 2026 and served as its President since August 27, 2021 until October 2024 and serves as Co-Founder of the Ovid Therapeutics Inc. He serves as Director of Graviton BioScience Corporation from May 2023. He is Member of Advisory Board at New Rhein Healthcare Investors LLC. From 1996 to 2000, Dr. Levin has experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. He serves as Executive Chair and Director at Ceryvyn Therapeutics Limited (formerly known as Opthea Limited) since October 12, 2020. He served as Global Head of Strategic Alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG from 2002 to 2007. He served as the Chief Executive Officer and President of Teva Pharmaceutical Industries Limited from May 9, 2012 to October 30, 2013. He served as the President of ZymoGenetics, Inc. since October 12, 2010. He served as the President of Medarex, Inc. since September 2009. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company. He served as Senior Vice President of Strategy, Alliances and Transactions at Bristol-Myers Squibb Company since 2010. He served as Senior Vice President of External Science Technology & Licensing at Bristol-Myers Squibb Company since September 29, 2007. He served as the Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research, Inc. from 2002 to 2007. He served as the Chief Executive Officer of Predix Pharmaceuticals Holdings Inc. From 1998 to 1999, he served as Managing Director of Perseus Capital LLC and from 1992 to 1998, he served as the President and Chief Executive Officer of Cadus Pharmaceutical Corporation. Prior to 1992, he served as Vice President of IG Laboratories, a wholly owned subsidiary of Genzyme Corporation. He has deep experience in the global pharmaceuticals and biotechnology industry. He served as the Chairman of Physiome Sciences Inc. He served as the Chairman of Cadus Pharmaceutical Corporation from 1996 to 1998. He served as an Independent Director of Biocon Limited since January 22, 2015 until January 23, 2020. He serves as a Director of ZappRx, Inc. and BIO, the Biotechnology Innovation Organization in the USA. He was an Independent Director of H. Lundbeck A/S since 2017 until 2024. He has served on the Boards of the Emerging Companies Section of the Biotechnology Industry Organization and on the Board of Vialactia, an agricultural genetics company. He serves as a Director of Biotechnology Institute, The. He served as a Director of Cellmark Forensics, Inc. since May 1998, ZymoGenetics, Inc. since October 12, 2010, Medarex, Inc. since September 2009 and Orchid Cellmark Inc. from May 1998 to August 11, 2003. He served as a Director of Predix Pharmaceuticals Holdings Inc. Previously, he served on the Board of various public and private biopharmaceutical companies. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. He is recognized among the 'Top 25 Most Influential People in the Biopharmaceutical Industry'. He is a recipient of Kermode Prize for work on novel hypertension drugs. He received Albert Einstein Award for Leadership in Life Sciences awarded by Mr. Shimon Peres and Officer's Cross of the Order of Merit of the Republic of Hungary. He has practiced Internal Medicine at University Hospitals in England, Switzerland and South Africa. He holds BA in Zoology in 1978, Masters of Arts in Cell Biology and a Doctorate (D. Phil) in Molecular Biology/DNA structure/Chromatin Structure from the University of Oxford and Degrees of Bachelor of Medicine in 1981, Bachelor of Surgery (MB and B. Chir) from the University of Cambridge.

Positions